<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN" "https://jats.nlm.nih.gov/publishing/1.2/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" dtd-version="1.2" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">IJMABHR</journal-id>
<journal-title-group><journal-title>International Journal of Medical and All Body Health Research</journal-title><abbrev-journal-title>IJMABHR</abbrev-journal-title></journal-title-group>
<issn pub-type="epub">2582-8940</issn>
<publisher><publisher-name>Anfo Publication House</publisher-name></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">336</article-id>
<article-id pub-id-type="doi">10.54660/IJMBHR.2025.6.2.67-70</article-id>
<title-group><article-title>Therapeutic Efficacy Observation of Rituximab Combined With Low-Dose Glucocorticoids in the Treatment of Idiopathic Membranous Nephropathy</article-title></title-group>
<contrib-group>
<contrib contrib-type="author"><name><surname>Ren</surname><given-names>Hui-min</given-names></name><xref ref-type="aff" rid="aff1"/></contrib>
<contrib contrib-type="author" corresp="yes"><name><surname>Quan</surname><given-names>Zheng-li</given-names></name><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff3"/></contrib>
<aff id="aff1"><label>1</label>Department of Medicine, Jingchu University of Technology, Jingmen 448000, China</aff>
<aff id="aff2"><label>2</label>Department of Nephrology, Jingmen Central Hospital, Jingmen 448000, China</aff>
<aff id="aff3"><label>3</label>Jingmen Central Hospital affiliated to Jingchu University of Technology, Jingmen 448000, China</aff>
</contrib-group>
<pub-date publication-format="electronic" date-type="pub"><year>2025</year></pub-date>
<volume>6</volume>
<issue>2</issue>
<fpage>67</fpage>
<lpage>70</lpage>
<history>
<date date-type="received"><day>09</day><month>03</month><year>2025</year></date>
<date date-type="accepted"><day>13</day><month>04</month><year>2025</year></date>
</history>
<permissions><license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-sa/4.0/?utm"><license-p>CC BY-NC-SA 4.0</license-p></license></permissions>
<self-uri xlink:href="https://www.allmedicaljournal.com/article/336/therapeutic-efficacy-observation-of-rituximab-combined-with-low-dose-glucocorticoids-in-the"/>
<self-uri content-type="pdf" xlink:href="https://www.allmedicaljournal.com/article/336/download"/>
<abstract><p>Objective: To compare the clinical efficacy and safety of rituximab (RTX) combined low-dose glucocorticoid for idiopathic membranous nephropathy (IMN). 

Methods: A total of 35 IMN patients were recruited from July，2019 to December, 2023. Control group (n=19): CTX combined glucocorticoid. Experimental group (n=26): rituximab combined low-dose glucocorticoid. The differences of 24-hour urinary protein, serum albumin, blood creatinine, anti-PLA2R antibody titer, disease re-mission rate and adverse reactions were compared between two groups before and at different timepoints post-treatment. 

Results: No significant inter-group differences existed in gender, age, body mass index, blood pressure, 24-hour urinary protein, serum albumin, blood creatinine, eGFR or anti-PLA2R antibody count pre-treatment (P&gt;0.05). At Month 6, 24-hour urinary protein declined markedly in 2 groups as compared with pre-treatment (P0.05). Anti-PLA2R-Ab level declined markedly in two groups post-treatment as compared with pre-treatment and the difference was not statistically significant (P&gt;0.05). In terms of disease remission, total effective rate reached 71.43% at Month 6. Meanwhile, recurrence rate was no significant inter-group difference existed in adverse reactions (P&gt;0.05). 

Conclusion: With a higher clinical remission rate without a higher incidence of adverse reactions, RTX combined low-dose glucocorticoid is more suitable for treating IMN. However, adverse reactions causing severe hypokalemia deserve greater attention</p></abstract>
<kwd-group kwd-group-type="author"><kwd>Idiopathic Membranous Nephropathy</kwd><kwd>Anti-CD20 Monoclonal Antibody</kwd><kwd>Rituximab</kwd></kwd-group>
</article-meta>
</front>
<back><ref-list><title>References</title>
<ref id="R1"><label>1</label><mixed-citation>Hou JH, Zhu HX, Zhou ML, et al. Changes in the spectrum of kidney diseases: an analysis of 40,759 biopsy-proven cases from 2003 to 2014 in China. Kidney Dis. 2018;4(1):10-19.</mixed-citation></ref>
<ref id="R2"><label>2</label><mixed-citation>Ronco P, Beck L, Debiec H, et al. Membranous nephropathy. Nat Rev Dis Primers. 2021;7:69.</mixed-citation></ref>
<ref id="R3"><label>3</label><mixed-citation>Couser WG. Primary membranous nephropathy. Clin J Am Soc Nephrol. 2017;12(6):983-997.</mixed-citation></ref>
<ref id="R4"><label>4</label><mixed-citation>Ronco P, Debiec H. Molecular pathogenesis of membranous nephropathy. Annu Rev Pathol. 2020;15:287-313.</mixed-citation></ref>
<ref id="R5"><label>5</label><mixed-citation>Beck LH Jr, Bonegio RGB, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361(1):11-21.</mixed-citation></ref>
<ref id="R6"><label>6</label><mixed-citation>Pavlasova G, Mraz M. The regulation and function of CD20: an &quot;enigma&quot; of B-cell biology and targeted therapy. Haematologica. 2020;105(6):1494-1506.</mixed-citation></ref>
<ref id="R7"><label>7</label><mixed-citation>Kidney Disease: Improving Global Outcomes Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(4S):S1-S276.</mixed-citation></ref>
<ref id="R8"><label>8</label><mixed-citation>Ponticelli C, Escoli R, Moroni G. Does cyclophosphamide still play a role in glomerular diseases? Autoimmun Rev. 2018;17(10):1022-1027.</mixed-citation></ref>
<ref id="R9"><label>9</label><mixed-citation>Fernández-Juárez G, Rojas-Rivera J, van de Logt AE, et al. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. Kidney Int. 2021;99(4):986-998.</mixed-citation></ref>
</ref-list></back>
</article>